Sugi Predict

Sugi Predict / Targets / BRD8

BRD8

Bromodomain-containing protein 8 · Q9H0E9 · BRD8 on Sugi Atlas →

3,348 patent compounds predicted against BRD8, 2,962 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16225268 SCHEMBL16225268 1.00 1/20
SCHEMBL16225383 SCHEMBL16225383 0.88 1/20
SCHEMBL16225532 SCHEMBL16225532 0.78 1/20
SCHEMBL16225562 SCHEMBL16225562 0.76 1/20
SCHEMBL16225789 SCHEMBL16225789 0.74 1/20
SCHEMBL16231382 SCHEMBL16231382 0.73 1/20
SCHEMBL16225514 SCHEMBL16225514 0.73 1/20
SCHEMBL16225155 SCHEMBL16225155 0.72 1/20
SCHEMBL16225443 SCHEMBL16225443 0.72 1/20
SCHEMBL16259151 SCHEMBL16259151 0.72 1/20
SCHEMBL16225592 SCHEMBL16225592 0.71 1/20
SCHEMBL16225149 SCHEMBL16225149 0.70 1/20
SCHEMBL16225287 SCHEMBL16225287 0.70 1/20
SCHEMBL16225958 SCHEMBL16225958 0.70 1/20
SCHEMBL16225392 SCHEMBL16225392 0.69 1/20
SCHEMBL16225306 SCHEMBL16225306 0.69 1/20
SCHEMBL16225423 SCHEMBL16225423 0.68 1/20
SCHEMBL16225253 SCHEMBL16225253 0.68 1/20
SCHEMBL16225416 SCHEMBL16225416 0.68 1/20
SCHEMBL16225498 SCHEMBL16225498 0.68 1/20

Clinical trials — most relevant to BRD8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 PHASE2COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer PHASE1RECRUITING
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRD8 binder may also engage these)

ProteinNameSimilarity
Q8R3B7 — 0.990 Q8R3B7 →
Q9WU42 — 0.989 Q9WU42 →
NCOR2 Nuclear receptor corepressor 2 0.984 landscape →
Q8K2W6 — 0.979 Q8K2W6 →
Q9HCE3 — 0.979 Q9HCE3 →
Q6NXK2 — 0.976 Q6NXK2 →
Q9Z2D6 — 0.976 Q9Z2D6 →
Q96N64 — 0.976 Q96N64 →
B3KU38 — 0.976 B3KU38 →
F7AQ22 — 0.976 F7AQ22 →
Q4KKX4 — 0.976 Q4KKX4 →
Q62511 — 0.975 Q62511 →
A0A1L8GR68 — 0.975 A0A1L8GR68 →
P0C6S7 — 0.975 P0C6S7 →
ZFP91 E3 ubiquitin-protein ligase ZFP91 0.974 landscape →
Q00566 — 0.974 Q00566 →
Q9BE73 — 0.974 Q9BE73 →
NCOR1 Nuclear receptor corepressor 1 0.973 landscape →
PHF13 PHD finger protein 13 0.973 landscape →
Q95LG8 — 0.973 Q95LG8 →
Q9Z103 — 0.973 Q9Z103 →
O75541 — 0.973 O75541 →
MECP2 Methyl-CpG-binding protein 2 0.973 landscape →
D4A7U2 — 0.972 D4A7U2 →
P97432 — 0.972 P97432 →
Q8BIZ1 — 0.972 Q8BIZ1 →
Q69Z61 — 0.972 Q69Z61 →
P49797 — 0.971 P49797 →
Q17R98 — 0.971 Q17R98 →
P49140 — 0.971 P49140 →